Abstract 1568P
Background
Lung cancer (LC) screening is an effective secondary preventive measure in decreasing LC mortality. Except for age and smoking history prediction models with additional variables were verified in different populations. In September 2020 the first pilot program for early detection of LC started in Vojvodina, Serbia. To increase LC positive findings we analyze characteristics of screening participants from September 2020 to April 2024.
Methods
Eligibility for LC screening is restricted to persons aged 50-74 years, with a smoking history of 30 pack-years, or 20 pack-years with additional risks; either active or quit smoking within the previous 10 years. Participants sign informed consent and fill out an online questionnaire with socio-demographic data (age, gender, marital, education, working status), smoking status (pack-years), exposure data (professional, tobacco exposure in childhood, in adulthood), BMI, alcohol consumption, symptoms of respiratory diseases, presence of chronic disease or cancer of other localization, and family history of LC. Screening results were reported by Lung RADS score (1 to 4). Differences between participants with positive (score 4) and negative or intermediate (score 1 to 3) results were analyzed.
Results
During the observed period, 61.3% (1690/2759) of screened were females. Positive screens were reported in 264(9.6%) of participants. Characteristics of participants divided by scores (4 vs score 1-3) showed differences in age (64.03±6.62 vs 61.54±6.71, p<0.001), BMI (25.35±3.87 vs 26.64±4.58, p<0.001), years of smoking (38.82±9.47 vs 37.01±8.60, p=0.001), pack-years (42.59±17.06 vs 39.49±16.20, p=0.003), appetite loss (11.4% vs 6.7%, p=0.005), and weight loss (14.4% vs 8.1%, p<0.001). Significant differences were observed between participants according to employment (p<0.001) and education level (p=0.022); retired (60.6% vs 44.3%) and finished primary school (14.0% vs 8.6%) were more common in score 4, while employed (43.2% vs 27.3%) and faculty education (23.7% vs 19.7%) in score 1-3.
Conclusions
Reaching more elderly and heavy smoker participants with lower BMI and lower education could increase the percentage of LC positive screening results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute for Pulmonary Diseases of Vojvodina.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10